BioMarin Pharmaceutical Inc (BMRN) shareholders
Close on Nov 18, 2026Market cap $11.89BP/E 161.7Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 19,373,309 | 10.00% | 13G (passive) amendment | Oct 31, 2026 |
| Primecap Management Co/Ca/ | 15,795,383 | 8.24% | 13G (passive) amendment | Jun 30, 2025 |
| Dodge & Cox | 13,994,063 | 7.40% | 13G (passive) amendment | Dec 31, 2023 |
| Viking Global Investors LP Joint filing with Halvorsen Ole Andreas (6.40%), Ott David C. (6.40%) and 1 more | 12,288,611 | 6.40% | 13G (passive) amendment | Jun 30, 2025 |
| Vanguard Capital Management | 10,113,219 | 5.25% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BMRN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 20,445,212 | 10.56% | $1.17B | +626,911 | 0.02% |
| Dodge & Cox | 14,844,930 | 7.67% | $849.43M | +283,171 | 0.44% |
| Primecap Management Co/Ca/ | 14,190,183 | 7.33% | $811.96M | −3,822 | 0.48% |
| Vanguard Capital Management LLC | 8,743,633 | 4.52% | $500.31M | +100,469 | 0.01% |
| Vanguard Portfolio Management LLC | 8,648,678 | 4.47% | $494.88M | +350,203 | 0.02% |
| Norges Bank | 8,207,954 | 4.24% | $469.66M | New | 0.05% |
| State Street Corp | 7,800,959 | 4.03% | $446.37M | +505,880 | 0.01% |
| Viking Global Investors LP | 7,616,563 | 3.93% | $435.82M | +554,486 | 1.24% |
| Vestal Point Capital, LP | 6,025,000 | 3.11% | $344.75M | +2,450,000 | 8.06% |
| Aqr Capital Management LLC | 5,699,541 | 2.94% | $322.54M | −1,977,000 | 0.11% |
| FMR LLC | 4,822,893 | 2.49% | $275.97M | +1,255,862 | 0.01% |
| Dimensional Fund Advisors LP | 4,075,714 | 2.11% | $233.22M | +272,784 | 0.04% |
| Geode Capital Management, LLC | 3,911,794 | 2.02% | $223.89M | +92,353 | 0.01% |
| Assenagon Asset Management S.A. | 3,524,172 | 1.82% | $201.65M | +1,603,514 | 0.13% |
| Capital Research Global Investors | 3,504,387 | 1.81% | $200.52M | +13,001 | 0.03% |
| Deep Track Capital, LP | 3,307,481 | 1.71% | $189.25M | +2,157,481 | 2.75% |
| Millennium Management LLC | 2,071,816 | 1.07% | $118.55M | −938,492 | 0.04% |
| Charles Schwab Investment Management Inc | 1,616,020 | 0.83% | $92.47M | +28,337 | 0.01% |
| First Trust Advisors LP | 1,606,273 | 0.83% | $91.91M | −66,218 | 0.05% |
| Northern Trust Corp | 1,558,104 | 0.80% | $89.15M | −28,280 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 564 | 196M | 100.0% | 87 / 204 | 196 / 77 | 33M | 19M |
| Q1 2026 | 559 | 184M | 94.9% | 92 / 213 | 164 / 67 | 42M | 27M |
| Q4 2025 | 539 | 189M | 97.5% | 102 / 168 | 210 / 127 | 36M | 27M |
| Q3 2025 | 577 | 180M | 93.1% | 75 / 225 | 201 / 74 | 17M | 22M |
| Q2 2025 | 582 | 185M | 95.6% | 86 / 243 | 186 / 81 | 28M | 29M |
| Q1 2025 | 584 | 186M | 96.2% | 100 / 242 | 176 / 55 | 19M | 15M |
| Q4 2024 | 544 | 184M | 95.0% | 91 / 202 | 184 / 92 | 18M | 18M |
| Q3 2024 | 555 | 183M | 94.7% | 87 / 198 | 198 / 86 | 38M | 20M |
| Q2 2024 | 560 | 188M | 97.1% | 88 / 194 | 198 / 80 | 30M | 32M |
| Q1 2024 | 559 | 191M | 98.9% | 67 / 196 | 205 / 53 | 20M | 19M |
| Q4 2023 | 548 | 190M | 98.0% | 86 / 180 | 204 / 50 | 24M | 17M |
| Q3 2023 | 520 | 183M | 94.3% | 43 / 191 | 192 / 76 | 19M | 13M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
484 funds held BMRN in Q2 2026, 44% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of BMRN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Dodge & Cox Stock Fund | 9,769,625 | 5.05% | $559.02M | 0.47% | Jun 30, 2026 |
| iShares Core S&P Mid-Cap ETF | 6,614,631 | 3.42% | $378.49M | 0.30% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 6,142,022 | 3.17% | $351.45M | 0.02% | Jun 30, 2026 |
| Vanguard Capital Opportunity Fund | 5,168,345 | 2.67% | $295.73M | 0.90% | Jun 30, 2026 |
| Vanguard Primecap Fund | 4,969,450 | 2.57% | $284.35M | 0.30% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 4,434,241 | 2.29% | $253.73M | 0.13% | Jun 30, 2026 |
| Capital World Growth & Income Fund | 2,576,251 | 1.33% | $147.59M | 0.09% | May 31, 2026 |
| Vanguard Small-Cap Growth Index Fund | 2,554,018 | 1.32% | $146.14M | 0.31% | Jun 30, 2026 |
| Fidelity Contrafund | 2,529,010 | 1.31% | $144.71M | 0.08% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 2,216,774 | 1.15% | $126.84M | 0.13% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,772,667 | 0.92% | $101.43M | 0.94% | Jun 30, 2026 |
| PRIMECAP Odyssey Aggressive Growth Fund | 1,412,415 | 0.73% | $84.77M | 1.15% | Jul 31, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund | 1,391,830 | 0.72% | $79.64M | 2.83% | Jun 30, 2026 |
| iShares Biotechnology ETF | 1,348,623 | 0.70% | $77.17M | 0.85% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 984,215 | 0.51% | $56.39M | 0.13% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Alexander Hardy | Chief Executive Officer, Director | 214,635 | 0.11% | Mar 19, 2026 |
| Gregory R. Friberg | EVP, Chief R&D Officer | 47,732 | 0.02% | Oct 1, 2026 |
| George Eric Davis | EVP, Chief Legal Officer | 61,003 | 0.03% | Sep 3, 2026 |
| Cristin Hubbard | EVP, Chief Commercial Officer | 42,472 | 0.02% | May 21, 2026 |
| Charles Greg Guyer | EVP, Chief Technical Officer | 84,140 | 0.04% | Mar 19, 2026 |
| Brian Mueller | EVP, Chief Financial Officer | 123,314 | 0.06% | Mar 19, 2026 |
| Rashmi Virendra Ramchandani | VP, Chief Accounting Officer | 25,610 | 0.01% | Jan 22, 2026 |
| Erin Burkhart | GVP, Chief Accounting Officer | 14,173 | 0.01% | May 20, 2025 |
| Robert M. Plenge | Director | 6,140 | 0.00% | Sep 14, 2026 |
| Mark J. Enyedy | Director | 21,040 | 0.01% | Jun 4, 2026 |
| Athena Countouriotis | Director | 21,040 | 0.01% | Jun 4, 2026 |
| Maykin Ho | Director | 35,500 | 0.02% | Jun 4, 2026 |
| Willard H. Dere | Director | 46,440 | 0.02% | Jun 4, 2026 |
| Barbara W. Bodem | Director | 21,045 | 0.01% | Jun 4, 2026 |
| Robert J. Hombach | Director | 49,360 | 0.03% | Jun 4, 2026 |
| Elizabeth M. Anderson | Director | 41,940 | 0.02% | Jun 4, 2026 |
| Timothy P. Walbert | Director | 17,686 | 0.01% | Jun 4, 2026 |
| Ian T. Clark | Director | 14,490 | 0.01% | Jun 4, 2026 |
| Richard A. Meier | Director | 126,926 | 0.07% | Feb 13, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Gregory R. Friberg EVP, Chief R&D Officer | Sep 30, 2026 | Tax withholding | −4,086 | $60.00 | $245.16K | 47,732 |
| Robert M. Plenge Director | Sep 10, 2026 | Award | +6,140 | – | – | 6,140 |
| George Eric Davis EVP, Chief Legal Officer | Sep 2, 2026 | Sale | −17,557 | $66.28 | $1.16M | 61,003 |
| Timothy P. Walbert Director | Jun 2, 2026 | Award | +7,490 | – | – | 17,270 |
| Maykin Ho Director | Jun 2, 2026 | Award | +7,490 | – | – | 35,500 |
| Athena Countouriotis Director | Jun 2, 2026 | Award | +7,490 | – | – | 21,040 |
| Willard H. Dere Director | Jun 2, 2026 | Award | +7,490 | – | – | 46,440 |
| Elizabeth M. Anderson Director | Jun 2, 2026 | Award | +7,490 | – | – | 41,940 |
| Ian T. Clark Director | Jun 2, 2026 | Award | +7,490 | – | – | 14,490 |
| Mark J. Enyedy Director | Jun 2, 2026 | Award | +7,490 | – | – | 21,040 |
| Robert J. Hombach Director | Jun 2, 2026 | Award | +7,490 | – | – | 49,360 |
| Barbara W. Bodem Director | Jun 2, 2026 | Award | +7,490 | – | – | 21,045 |
| Cristin Hubbard EVP, Chief Commercial Officer | May 20, 2026 | Tax withholding | −2,318 | $50.20 | $116.36K | 42,472 |
| Gregory R. Friberg EVP, Chief R&D Officer | May 7, 2026 | Sale | −3,281 | $53.85 | $176.68K | 51,818 |
| George Eric Davis EVP, Chief Legal Officer | Mar 18, 2026 | Tax withholding | −1,273 | $56.05 | $71.35K | 78,560 |
| Charles Greg Guyer EVP, Chief Technical Officer | Mar 17, 2026 | Tax withholding | −1,693 | $56.05 | $94.89K | 84,140 |
| Alexander Hardy Chief Executive Officer, Director | Mar 17, 2026 | Tax withholding | −4,252 | $56.05 | $238.32K | 214,635 |
| Brian Mueller EVP, Chief Financial Officer | Mar 17, 2026 | Tax withholding | −2,117 | $56.05 | $118.66K | 123,314 |
| Gregory R. Friberg EVP, Chief R&D Officer | Mar 17, 2026 | Tax withholding | −1,629 | $56.05 | $91.31K | 55,099 |
| Cristin Hubbard EVP, Chief Commercial Officer | Mar 17, 2026 | Tax withholding | −1,245 | $56.05 | $69.78K | 44,790 |
| Gregory R. Friberg EVP, Chief R&D Officer | Mar 16, 2026 | Award | +19,150 | – | – | 56,728 |
| Cristin Hubbard EVP, Chief Commercial Officer | Mar 16, 2026 | Award | +15,410 | – | – | 46,035 |
| Brian Mueller EVP, Chief Financial Officer | Mar 16, 2026 | Award | +18,740 | – | – | 125,431 |
| Charles Greg Guyer EVP, Chief Technical Officer | Mar 16, 2026 | Award | +14,990 | – | – | 85,833 |
| George Eric Davis EVP, Chief Legal Officer | Mar 16, 2026 | Tax withholding | −7,177 | $58.51 | $419.93K | 65,263 |
| George Eric Davis EVP, Chief Legal Officer | Mar 16, 2026 | Award | +14,570 | – | – | 79,833 |
| Alexander Hardy Chief Executive Officer, Director | Mar 16, 2026 | Award | +62,440 | – | – | 218,887 |
| Brian Mueller EVP, Chief Financial Officer | Mar 13, 2026 | Tax withholding | −9,945 | $58.51 | $581.88K | 106,691 |
| Charles Greg Guyer EVP, Chief Technical Officer | Mar 13, 2026 | Tax withholding | −9,109 | $58.51 | $532.97K | 70,843 |
| Alexander Hardy Chief Executive Officer, Director | Mar 13, 2026 | Tax withholding | −2,941 | $58.51 | $172.08K | 156,447 |
| Charles Greg Guyer EVP, Chief Technical Officer | Mar 11, 2026 | Sale | −16,486 | $60.46 | $996.74K | 79,953 |
| Gregory R. Friberg EVP, Chief R&D Officer | Feb 26, 2026 | Sale | −6,326 | $60.38 | $381.96K | 37,578 |
| George Eric Davis EVP, Chief Legal Officer | Feb 26, 2026 | Sale | −26,061 | $61.36 | $1.60M | 72,453 |
| Brian Mueller EVP, Chief Financial Officer | Feb 25, 2026 | Award | +6,683 | – | – | 106,839 |
| Brian Mueller EVP, Chief Financial Officer | Feb 25, 2026 | Award | +7,230 | – | – | 114,069 |
| Brian Mueller EVP, Chief Financial Officer | Feb 25, 2026 | Award | +2,569 | – | – | 116,638 |
| George Eric Davis EVP, Chief Legal Officer | Feb 25, 2026 | Award | +6,177 | – | – | 89,467 |
| George Eric Davis EVP, Chief Legal Officer | Feb 25, 2026 | Award | +6,675 | – | – | 96,142 |
| George Eric Davis EVP, Chief Legal Officer | Feb 25, 2026 | Award | +2,372 | – | – | 98,514 |
| Charles Greg Guyer EVP, Chief Technical Officer | Feb 25, 2026 | Award | +6,176 | – | – | 87,393 |
| Charles Greg Guyer EVP, Chief Technical Officer | Feb 25, 2026 | Award | +6,675 | – | – | 94,068 |
| Charles Greg Guyer EVP, Chief Technical Officer | Feb 25, 2026 | Award | +2,371 | – | – | 96,439 |
| Rashmi Virendra Ramchandani VP, Chief Accounting Officer | Jan 20, 2026 | Award | +7,070 | – | – | 25,610 |
| Rashmi Virendra Ramchandani VP, Chief Accounting Officer | Jan 20, 2026 | Award | +18,540 | – | – | 18,540 |
| Richard A. Meier Director | Dec 30, 2025 | Gift | −500 | – | – | 126,926 |
| Alexander Hardy Chief Executive Officer, Director | Dec 1, 2025 | Tax withholding | −16,570 | $55.03 | $911.85K | 159,388 |
| Charles Greg Guyer EVP, Chief Technical Officer | Oct 31, 2025 | Award | +62 | $45.54 | $2.82K | 81,217 |
| Cristin Hubbard EVP, Chief Commercial Officer | Oct 31, 2025 | Award | +80 | $45.54 | $3.64K | 30,625 |
| Gregory R. Friberg EVP, Chief R&D Officer | Oct 31, 2025 | Award | +398 | $45.54 | $18.12K | 43,904 |
| Gregory R. Friberg EVP, Chief R&D Officer | Sep 30, 2025 | Tax withholding | −3,304 | $54.16 | $178.94K | 43,506 |
| Ian T. Clark Director | Aug 1, 2025 | Award | +7,000 | – | – | 7,000 |
| Barbara W. Bodem Director | May 20, 2025 | Award | +6,650 | – | – | 13,555 |
| Richard A. Meier Director | May 20, 2025 | Award | +6,650 | – | – | 127,426 |
| Mark J. Enyedy Director | May 20, 2025 | Award | +6,650 | – | – | 13,550 |
| Maykin Ho Director | May 20, 2025 | Award | +6,650 | – | – | 28,010 |
| Timothy P. Walbert Director | May 20, 2025 | Award | +6,650 | – | – | 9,780 |
| Elizabeth M. Anderson Director | May 20, 2025 | Award | +6,650 | – | – | 34,450 |
| Athena Countouriotis Director | May 20, 2025 | Award | +6,650 | – | – | 13,550 |
| Cristin Hubbard EVP, Chief Commercial Officer | May 20, 2025 | Tax withholding | −2,155 | $59.93 | $129.15K | 30,545 |
| Willard H. Dere Director | May 20, 2025 | Award | +6,650 | – | – | 38,950 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of BioMarin Pharmaceutical's stock actually held short. Settlement fails (shares not delivered on time) peaked at 47,834 shares on Sep 2, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| George Eric Davis Officer | Sep 2, 2026 | 17,557 | $1.16M | Sep 2, 2026 | Restricted Stock Vesting |
| Gregory R. Friberg Officer | May 7, 2026 | 3,281 | $176.68K | May 7, 2026 | Restricted Stock Vesting |
| Charles Greg Guyer Officer | Mar 11, 2026 | 16,486 | $996.75K | Mar 11, 2026 | Restricted Stock Vesting |
| Gregory R. Friberg Officer | Feb 26, 2026 | 6,326 | $381.94K | Feb 26, 2026 | Restricted Stock Vesting |
| George Eric Davis Officer | Feb 26, 2026 | 26,061 | $1.60M | Feb 26, 2026 | Stock Option Exercise |
| Erin Burkhart Officer | May 20, 2025 | 1,786 | $105.93K | May 20, 2025 | Restricted Stock Vesting |
| Cristin Hubbard Officer | May 2, 2025 | 273 | $17.72K | May 2, 2025 | ESPP Purchase |
| Erin Burkhart Officer | Mar 19, 2025 | 1,295 | $92.62K | Mar 19, 2025 | Restricted Stock Vesting |
| Charles Greg Guyer Officer | Mar 6, 2025 | 7,034 | $501.36K | Mar 6, 2025 | Restricted Stock Vesting |
| Erin Burkhart Officer | Feb 24, 2025 | 1,344 | $91.90K | Feb 24, 2025 | Restricted Stock Vesting |
| Charles Greg Guyer Officer | Nov 12, 2024 | 5,278 | $350.32K | Nov 12, 2024 | Restricted Stock Vesting |
| Erin Burkhart Officer | Aug 13, 2024 | 714 | $64.26K | Aug 13, 2024 | Restricted Stock Vesting |
| Jeffrey Robert Ajer Officer | Jun 4, 2024 | 5,000 | $384.00K | Jun 4, 2024 | Restricted Stock Vesting |
| Jean Jacques Bienaime Former Director | May 31, 2024 | 31,000 | $2.31M | May 31, 2024 | Option Granted - 06/04/2014 |
| Brian Mueller Officer | May 30, 2024 | 5,000 | $375.95K | May 30, 2024 | Option Granted - 06/04/2014 |
Congress trades
7 trades in BioMarin Pharmaceutical reported by 5 members of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Daniel Goldman NY10 | Sold | Mar 6, 2023 | $1K–15K | Apr 17, 2023 |
| Lamar Smith TX21 | Sold | Feb 12, 2018 | $1K–15K | Mar 7, 2018 |
| Alan S. Lowenthal CA47 · spouse | Bought | Jan 18, 2018 | $1K–15K | Jan 21, 2018 |
| Alan S. Lowenthal CA47 · spouse | Bought | Jan 17, 2018 | $1K–15K | Jan 21, 2018 |
| K. Michael Conaway TX11 · spouse | Sold | Sep 12, 2016 | $1K–15K | Oct 12, 2016 |
| Thomas MacArthur NJ03 | Sold | Jan 27, 2015 | $1K–15K | Mar 5, 2015 |
| Lamar Smith TX21 | Bought | Nov 14, 2014 | $1K–15K | Dec 8, 2014 |
See a number that looks wrong?